参附注射液在心脏骤停综合征中的作用

目的探讨参附注射液在心脏骤停综合征（PCAS）中的治疗作用及机制。方法60例患者被随机分为两组，对照组予常规治疗，治疗组在常规治疗基础上加用参附注射液静滴。疗程14d。治疗过程中定期评估患者血流动力学指标及急性生理学及慢性健康状况评分Ⅱ（APACHEⅡ）。结果治疗组血流动力学指标明显改善，APACHEⅡ评分及存活率明显高于对照组（均P〈0．05）。结论参附注射液在心脏骤停综合征患者的治疗中能稳定血流动力学、改善心脏功能，明显提高心脏骤停综合征患者的生存率。

Clinical exploration on Shenfu injection on post-cardiac arrest syndrome

Objective To investigate Shenfu injection＇s clinical effect and mechanism on post cardiac arrest syndrome （PCAS）. Methods Sixty PCAS patients were randomly divided into the control group and the treatment group. In addition to the conventional therapy applied in both groups, the intravenous instillation of Shenfu Injection daily lasting for 14 days was adopted in the treatment group. Hemodynamics and APACHE Ⅱ of patients were regular assessed in the treatment process. Results Compared to control group, the indicators of Hemodynamics were significantly improved, APACHE Ⅱ and survival rate were significantly higher （P〈 0.05） in the treatment group. Conclusion The beneficial effect of Shenfu Injection may stabilize hemodynamics, improve cardiac function, and significantly improve the survival rate of the patients.